Pyomyositis (MONDO:0019168): A Comprehensive Disease Characterization

Category: Infectious Disease | MONDO: 0019168 | ICD-10: M60.0 | ICD-11: FB32.0 | MeSH: D011649

Evidence base: 15 confirmed findings across 5 investigation iterations, drawn from 58 primary papers and reviews. All clinical/epidemiologic data are human (hospital-based case series, cohorts, systematic reviews, administrative datasets); mechanistic support includes murine in vivo models. Pyomyositis is not a genetic disease, so genetic/inheritance sections are largely Not Applicable.

Summary

Pyomyositis is a primary pyogenic bacterial infection of striated skeletal muscle, most often caused by Staphylococcus aureus, that produces an intramuscular abscess in a large muscle group—classically the thigh, iliopsoas, obturator, or gluteal muscles. It is fundamentally an acquired infectious disease, not a genetic or heritable disorder; there are no causal human genes, and host susceptibility is instead governed by acquired immunocompromising states. The disease was historically termed "tropical pyomyositis" because of its high incidence in tropical climates, but it is increasingly recognized in temperate, high-income countries where its incidence has more than tripled in recent decades, largely because of its association with immunodeficiency states such as HIV/AIDS, diabetes mellitus, malignancy, and organ transplantation.

The pathophysiology is best understood as a two-hit process: transient or occult S. aureus bacteremia seeds skeletal muscle that has been rendered locally vulnerable by antecedent trauma or vigorous exercise. Normal skeletal muscle is intrinsically resistant to hematogenous infection, so muscle injury—reported in roughly one-third of patients—is thought to be a necessary permissive lesion, a mechanism directly supported by a murine "Trojan Horse" model in which intravenous MRSA alone produced no muscle infection unless muscle injury and ischemia were also present. Once seeded, the infection evolves through the classic three-stage Chiedozi progression: an invasive stage (diffuse inflammation, antibiotic-responsive), a suppurative stage (abscess formation, requiring drainage—the stage at which most patients present), and a late septic stage (bacteremia, metastatic abscesses, septic shock).

Diagnosis rests on MRI, which is essentially 100% sensitive and is the modality of choice for defining site, extent, and multifocality; ultrasound and blood cultures are less reliable (culture-negative disease is common). Treatment is stage-dependent: anti-staphylococcal antibiotics alone cure early disease, while drainage plus antibiotics is required once an abscess forms. Prognosis is excellent with timely intervention—most patients recover full function—but reported mortality ranges from 1% to 23%, driven by diagnostic delay, sepsis, hypoalbuminemia, inappropriate initial antibiotics, and advanced disease at presentation. Because the disease is non-heritable and no S. aureus vaccine exists, prevention relies on control of predisposing conditions, S. aureus decolonization, and early detection.

Section 1 — Disease Information

Pyomyositis (PM) is formally defined as "a primary pyogenic infection of the striated skeletal muscle" (PMID: 29274860). It is characterized by intramuscular abscess formation arising from hematogenous spread of bacteria to muscle. It is described as "a common masquerading disease that is frequently misdiagnosed" (PMID: 27090546) because its early clinical features are non-specific and overlap with many soft-tissue conditions.

Key identifiers:

Synonyms / alternative names: tropical pyomyositis, tropical myositis, myositis tropicans, pyogenic myositis, primary bacterial pyomyositis, purulent infectious myositis, and Lambo abscess.

Information source type: The evidence base is a mixture of aggregated disease-level resources (systematic reviews, meta-analyses, population databases such as the US National Inpatient Sample) and individual-patient sources (hospital-based case series, cohort studies, and case reports). There is no single genetic or EHR-derived registry; the knowledge base is predominantly clinical-observational.

Section 2 — Etiology

Primary cause: Pyomyositis is an infectious disease. The dominant causal factor is bacterial infection of skeletal muscle, overwhelmingly by Staphylococcus aureus (see Section 5). It is not genetic, and there are no Mendelian causal factors.

Risk factors (environmental / host): The disease is strongly associated with acquired immunocompromise. A systematic review and meta-analysis found pyomyositis significantly associated with HIV infection (OR = 4.82; 95% CI 1.67–13.92) and with fulfilling an AIDS surveillance definition (OR = 6.08; 95% CI 2.79–13.23) (PMID: 34407271). A US population-based study reported "significant association of pyomyositis with HIV, types 1 and 2 diabetes mellitus, hematologic malignancy, organ transplant, malnutrition, chronic kidney disease, obesity, and rheumatoid arthritis" (PMID: 32147332). In tropical series, "a concurrent state of immunodeficiency is observed in up to 75% of tropical PM cases" (PMID: 27090546). Additional environmental/behavioral risk factors include minor trauma, vigorous physical activity, and injection drug use; male sex and young age are strong demographic risk factors (Section 3).

Genetic risk factors (host): None identified. There are no known susceptibility loci, causal variants, or modifier genes in humans. This section is Not Applicable at the host level.

Protective factors: No genetic protective factors are known. Environmental/host protective factors are the inverse of the risk factors—immune competence, glycemic control, antiretroviral therapy with immune reconstitution, good nutrition, skin hygiene, and avoidance of muscle trauma.

Gene–environment interactions (pathogen side): The relevant "genetic" element is bacterial virulence. S. aureus strains carrying Panton-Valentine leukocidin (PVL; genes lukS-PV/lukF-PV) interact with the host to produce more severe disease: "Staphylococcus aureus strains carrying the genes encoding Panton-Valentine leukocidin (pvl-positive) are associated with more febrile days and higher complication rates" (PMID: 16452363). Thus the disease outcome is shaped by an interaction between pathogen genotype and host immune/tissue status rather than host germline variation.

Section 3 — Phenotypes

The clinical phenotype is a triad of fever, localized muscle pain/swelling, and functional impairment. A pediatric systematic review found "Fever, painful limp, and localized pain were the most common presenting symptoms" (PMID: 34411048). In adults, myalgia and fever dominate: "Common presenting symptoms were myalgias [50 (74.62%)] and fever [49 (73.13%)]" (PMID: 19763666).

Phenotype characteristics: - Age of onset: Bimodal in reports—young adults (mean 29.9 ± 14.8 yr in a North India cohort) and children (mean age ~8 yr in pediatric series). Predominantly a disease of children and young adults. - Severity: Variable—from indolent localized muscle pain to fulminant septic shock. - Progression: Subacute and progressive through three stages if untreated (Section 8); self-limited once appropriately treated. - Time to diagnosis: Mean ~6.6 ± 3.05 days (PMID: 34411048).

Quality of life: Acute functional impairment (inability to walk/use the affected limb) is common (~83% in one pediatric series), but with timely treatment full functional recovery is the norm—"All patients improved without functional impairment at 6-month follow-up" (PMID: 40440680). In aseptic/autoinflammatory pyomyositis (e.g., Behçet disease), presentations can include a palpable muscle mass, severe myalgia, and ~13-fold elevated creatine kinase (PMID: 41371187).

Section 4 — Genetic / Molecular Information

This section is largely Not Applicable at the host level. Pyomyositis is an acquired bacterial infection, not a Mendelian/heritable disorder. There are no causal human genes, no pathogenic germline variants, no chromosomal abnormalities, no inheritance pattern, no penetrance/expressivity, no founder effects, and no carrier frequencies (PMID: 34407271; PMID: 32147332). Genetic testing is not indicated for diagnosis; microbiological culture and MRI are used instead.

The relevant molecular determinants are bacterial virulence genes: - lukS-PV / lukF-PV encode Panton-Valentine leukocidin, a bicomponent pore-forming leukotoxin. PVL-positive strains cause more severe, complicated musculoskeletal disease: "Staphylococcus aureus strains carrying the genes encoding Panton-Valentine leukocidin (pvl-positive) are associated with more febrile days and higher complication rates" (PMID: 16452363). Severe/life-threatening PVL-SA infections including pyomyositis are documented in children (PMID: 31567961; PMID: 33629932). - MRSA (methicillin resistance, mecA) strains are increasingly reported, particularly in India, and complicate empiric therapy.

Epigenetics: Not applicable to host pathogenesis.

Section 5 — Environmental / Microbiological Information

Infectious agents (the core etiology):

S. aureus dominance is repeatedly confirmed: "Tropical pyomyositis is a serious infectious disease characterised by the formation of abscesses in the skeletal muscles and is primarily caused by Staphylococcus aureus" (PMID: 39971676) and "Staphylococcus aureus was the main organism isolated" (PMID: 34407271). In a Portuguese pediatric series, MSSA accounted for 36.0% of isolates. In the immunocompromised, the microbiology shifts: "Immunocompromised hosts are more likely to be affected by Gram-negative organisms, Mycobacterium tuberculosis, opportunistic infections such as fungal pathogens, non-tuberculous mycobacteria, and Nocardia species" (PMID: 39971676).

Environmental / lifestyle factors: Tropical climate, minor trauma, vigorous exercise, injection drug use (e.g., oesophageal pyomyositis in an IVDU, PMID: 25125141), and immunosuppressive states. Non-infectious (aseptic) pyomyositis is rare and occurs in autoinflammatory conditions such as Behçet disease (PMID: 41371187).

CHEBI-relevant entities: the causative organism's PVL toxin (protein), and therapeutic antibiotics (see Section 12).

Section 6 — Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Transient / occult bacteremia — S. aureus enters the bloodstream (from skin, mucosa, or minor breach). Leads to circulating bacteria that transit through muscle capillaries.
2. Antecedent muscle injury — trauma or vigorous exercise (reported in ~31–38% of cases; PMID: 40440680) produces a locus minoris resistentiae with local ischemia and hematoma. Results in a microenvironment that impairs bacterial clearance. (This step is causally required — see the "Trojan Horse" experiment below.)
3. Muscle seeding and proliferation (invasive stage) — bacteria colonize the damaged muscle and multiply over ~1–2 weeks. Leads to diffuse muscle inflammation without discrete abscess.
4. Neutrophil-mediated suppuration + toxin production (suppurative stage) — neutrophil influx, tissue necrosis, and PVL-mediated leukocyte lysis. Results in an intramuscular abscess (weeks 2–3).
5. Branch — local extension: abscess extends to adjacent bone (osteomyelitis), joint (septic arthritis), or fascia.
6. Branch — hematogenous dissemination (late/septic stage): leads to bacteremia, metastatic abscesses, septic emboli, endocarditis/pancarditis, septic shock, and multi-organ dysfunction (AKI, DVT, compartment syndrome).

Detailed mechanism

Why muscle is normally spared, and why injury matters. Skeletal muscle is intrinsically resistant to hematogenous bacterial seeding. The pivotal experimental demonstration is a murine "Trojan Horse" model in which "No SSIs were observed in mice injected intravenously with MRSA" unless muscle injury and ischemia were also induced ("mice were subjected to a surgical injury (30% hepatectomy) and rectus muscle injury and ischemia before skin closure") (PMID: 28187042). This shows bacteremia alone is insufficient; a second hit of muscle injury is required for seeding—mechanistically, circulating neutrophils carry bacteria into the injured, ischemic muscle. This directly explains the clinical epidemiology: "The disease primarily affects men and young adults, often following minor trauma" (PMID: 39971676).

Immune / cellular processes. Pyomyositis is a neutrophil-driven (pyogenic) infection (GO:0006954 inflammatory response; GO:0006935 chemotaxis). Impaired cell-mediated and neutrophil immunity—from HIV/AIDS, chemotherapy-induced neutropenia, hematologic malignancy, or diabetes—predisposes to disease. A striking clinical illustration is pyomyositis emerging during the chemotherapy "nadir" of transient neutropenia (PMID: 38090454).

Toxin-mediated tissue damage. PVL is a pore-forming leukotoxin that lyses neutrophils, causing tissue necrosis and severe/metastatic disease. PVL genes are "associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children" (PMID: 16452363), and PVL-positive strains drive more complications requiring surgery and longer hospitalization (PMID: 31567961; PMID: 33629932).

Upstream vs downstream. Upstream: bacteremia + muscle injury/ischemia + host immunocompromise. Midstream: bacterial proliferation, neutrophil recruitment, toxin release. Downstream: abscess formation, local extension, hematogenous dissemination, sepsis.

Cell types / tissues (suggested ontology terms): skeletal muscle cell / myofiber (CL:0000188), neutrophil (CL:0000775), macrophage (CL:0000235); skeletal muscle tissue (UBERON:0001134).

Section 7 — Anatomical Structures Affected

Primary tissue: skeletal (striated) muscle — UBERON:0001134. Usually a single large muscle group is involved, but disease is multifocal in ~12–40% of cases.

Distribution (muscle groups): The pelvis and lower limb predominate. A pediatric systematic review reported: "Pelvis, lower extremity, trunk and spine, in descending order, were the most commonly affected locations. Iliopsoas, obturator musculature, and gluteus musculature were the most commonly affected muscle groups" (PMID: 34411048). In adults, the thigh predominates: "Most common site of involvement was thigh muscles (n = 29, 46.8%)" (PMID: 29338140); in the Sharma cohort the iliopsoas was most common (46.26%).

Lateralization: typically unilateral.

Secondary / complication sites (body systems): bone (osteomyelitis), joints (septic arthritis, facet joint — PMID: 38449920), heart (endocarditis/pancarditis — PMID: 22538039), lungs (septic emboli/necrotizing pneumonia — PMID: 32623976), kidney (AKI), and veins (DVT). Body systems: musculoskeletal (primary), cardiovascular, respiratory, renal.

Subcellular: not a primary feature; relevant GO cellular components pertain to the pathogen (bacterial cell wall/membrane) rather than a host organelle defect.

Section 8 — Temporal Development

Onset: subacute; typically over days to ~2 weeks. Mean time to diagnosis ~6.6 days (PMID: 34411048). Age of onset predominantly children and young adults.

The classic three-stage (Chiedozi) progression:

Most patients present in stage 2: "Forty-nine patients (79%) presented in the suppurative stage of illness" (PMID: 29338140), reflecting diagnostic delay. Stage determines treatment: "The appropriate antibiotic therapy provides a rapid regression of symptoms during the early stage of pyomyositis. In cases of MRI-confirmed abscess, surgical treatment is indicated" (PMID: 28248876). Early-stage pediatric cases can show "marked improvement within 3 days" on antibiotics alone (PMID: 29274860).

Course & duration: acute/subacute and self-limited once appropriately treated; it is not chronic or relapsing-remitting. Remission is treatment-induced. The critical intervention window is the invasive stage, when antibiotics alone can achieve cure before abscess formation.

Section 9 — Inheritance and Population (Epidemiology)

Inheritance: Not Applicable — non-genetic, non-heritable infectious disease. No inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effects, consanguinity role, or carrier frequency.

Epidemiology / demographics: - Sex & age: strong male, young predominance — "Males under the age of 20 predominated, and mortality of up to 20% was reported" (PMID: 34407271). North India cohort: mean age 29.9 ± 14.8 yr, 54/62 male (PMID: 29338140). Portuguese pediatric series: 75.9% male, median age 8 yr. - Geographic distribution: historically tropical ("tropical pyomyositis"), now increasingly temperate. A US population study found "a concerning more than three-fold increase in the incident pyomyositis admissions over our study period" (2002–2014), with affected patients younger, more likely male and Black, and more cases in the West and South (PMID: 32147332). - Prevalence/incidence: precise population rates are not well established; it remains uncommon but rising in temperate high-income settings, and is far more common in the tropics.

Section 10 — Diagnostics

Imaging (cornerstone): MRI is the modality of choice — "Magnetic resonance imaging had 100% sensitivity, whereas 40.7% of ultrasounds were inconclusive" (PMID: 40440680) and "Magnetic resonance imaging (MRI) is the modality of choice for defining the site and extent of disease, detecting multiple foci, and guiding surgical planning" (PMID: 41127115). Point-of-care ultrasound can differentiate pyomyositis from cellulitis and "led to an earlier diagnosis of PM and directly affected the immediate patient care" (PMID: 25245285). CT is useful for deep-core muscle disease.

Laboratory / microbiology: Elevated inflammatory markers (WBC, ESR, CRP) are characteristic; creatine kinase is often normal or only mildly elevated in bacterial pyomyositis (a useful discriminator from primary myopathies/aseptic myositis, where CK can be markedly elevated). Cultures: blood cultures positive in ~40%, pus cultures in ~33%; culture-negative disease is common. Definitive microbiology comes from aspirated/drained pus.

Histopathology / biopsy: confirms suppurative myositis; in aseptic forms reveals "granulocytic-necrotizing infiltrates and fibrinoid vascular necrosis" (PMID: 41371187).

Genetic / omics testing: Not indicated (non-genetic disease). Molecular microbiology (e.g., CBNAAT/line-probe assay for tuberculous pyomyositis, PMID: 41626125) may be used to identify atypical pathogens.

Differential diagnosis: cellulitis, deep vein thrombosis (notably mimicked in SLE — "Pyomyositis may mimic deep vein thrombosis and be misdiagnosed" PMID: 35260400), necrotizing fasciitis, septic arthritis, osteomyelitis, muscle contusion/hematoma/strain, soft-tissue sarcoma, thrombophlebitis, and other infective myositides (streptococcal necrotizing myositis, tuberculous/melioidosis myositis). Imaging is central to distinguishing these entities.

Section 11 — Outcome / Prognosis

Overall: Prognosis is good with timely diagnosis and treatment; most patients achieve full functional recovery ("All patients improved without functional impairment at 6-month follow-up" — PMID: 40440680). However, reported mortality ranges 1–23%, driven largely by delay and sepsis.

Predictors of mortality: In a North India cohort of 67 patients, "Twenty-eight patients developed sepsis and seven died" (~10% mortality), with "a statistically significant association between higher SOFA score, lower Glasgow coma scale, higher pulse rate, lower blood pressure, raised blood urea, raised serum creatinine" (PMID: 19763666). An independent cohort found "Lower first-day serum albumin, initial inappropriate antibiotic therapy and advanced form of the disease at presentation were associated with increased in-hospital mortality" (PMID: 29338140).

Complications: sepsis/septic shock, metastatic abscesses, septic emboli/necrotizing pneumonia, osteomyelitis, septic arthritis, endocarditis/pancarditis, acute kidney injury, DVT, and compartment syndrome.

Section 12 — Treatment

Principle: stage-dependent combination of anti-staphylococcal antibiotics + source control (drainage).

Pharmacotherapy (NCIT: Antibiotic Therapy): - Empiric anti-staphylococcal agents: flucloxacillin (MSSA), vancomycin (MRSA), with clindamycin or linezolid added as anti-toxin agents for PVL-producing strains (these suppress bacterial protein/toxin synthesis). - Portuguese series: IV flucloxacillin + clindamycin in 55.2%, median 14 days IV and 29 days total (PMID: 40440680). - Pediatric systematic review: mean 9.5 ± 4.0 days IV and 22.7 ± 7.2 days oral antibiotics (PMID: 34411048).

Surgical / interventional (NCIT: Incision and Drainage): Drainage is required once an abscess forms. In the pediatric review, "Medical management alone was successful in 40% of cases (143/361)", with the remainder requiring drainage (open 91.3%, percutaneous 8.7%) (PMID: 34411048). Predictors of surgical need: "Painful limp, fever, and larger values of white cell count and erythrocyte sedimentation rate were associated with an increased need for surgery" (PMID: 34411048).

Supportive care: analgesia, fluid/hemodynamic support, ICU care for septic stage, treatment of underlying immunocompromise.

Treatment strategy / algorithm:

Suspected pyomyositis → MRI
   ├─ Invasive stage (no abscess) → IV anti-staph antibiotics → step down to oral
   └─ Suppurative/abscess → Drainage (image-guided or open) + antibiotics
                              └─ PVL/severe → add anti-toxin agent (clindamycin/linezolid)
   Septic stage → aggressive drainage + broad IV antibiotics + ICU support

Pharmacogenomics / advanced therapeutics (gene/cell/RNA therapy, immunotherapy): Not applicable — this is a treatable bacterial infection.

Outcomes: With combined therapy, functional recovery is excellent (see Section 11).

Section 13 — Prevention

No vaccine exists for pyomyositis or for S. aureus (multiple S. aureus vaccine candidates have failed in trials). Prevention is largely secondary/tertiary.

• Primary prevention: control predisposing conditions (glycemic control, antiretroviral therapy/immune reconstitution in HIV, nutrition), skin hygiene, prompt wound care, avoidance of muscle trauma and injection drug use. S. aureus decolonization is the principal targeted strategy: "S aureus colonization is a significant risk factor for subsequent infection; thus, surveillance and decolonization with topical antimicrobials and antiseptics remain the mainstay of prevention" (PMID: 42624765). Decolonization uses intranasal mupirocin and chlorhexidine bathing, though effectiveness wanes and drives resistance (PMID: 41276461).
• Secondary prevention: early recognition and imaging (MRI/point-of-care ultrasound) to catch the invasive stage before abscess forms, enabling cure with antibiotics alone (PMID: 25245285).
• Tertiary prevention: adequate drainage and appropriate antibiotics to prevent sepsis, metastatic abscesses, osteomyelitis, and contractures.
• Genetic/newborn screening: Not applicable (non-heritable).

Section 14 — Other Species / Natural Disease

• Model host species: Mus musculus (NCBITaxon:10090) is the principal experimental host (Section 15).
• Causative pathogen taxonomy: Staphylococcus aureus (NCBITaxon:1280).
• Natural disease in other species: Pyomyositis as a distinct clinical entity is chiefly described in humans; S. aureus muscle/soft-tissue abscesses occur across mammals but a dedicated veterinary "pyomyositis" literature is limited. No heritable animal ortholog exists because the disease is infectious, not genetic.
• Zoonotic potential: S. aureus (including MRSA) can transmit between humans and animals, but pyomyositis itself is not classically a zoonosis.
• Comparative biology: The murine muscle-injury model recapitulates the trauma-dependent seeding mechanism, indicating conservation of the host-tissue vulnerability principle (PMID: 28187042).

Section 15 — Model Organisms

There is no dedicated genetic "pyomyositis" model, because the disease is infectious and non-heritable. The relevant systems are induced infection models:

• Phenotype recapitulation: The Trojan Horse model reproduces trauma-dependent muscle abscess formation ("mice were subjected to a surgical injury (30% hepatectomy) and rectus muscle injury and ischemia before skin closure", PMID: 28187042); the neutropenic thigh model ("mice with a Staphylococcus aureus infection in the thigh muscle", PMID: 26514291) mirrors the human predisposition of immunocompromise.
• Limitations: These models emphasize bacterial burden and drug response rather than the full three-stage natural history and chronic abscess of human disease, and they do not model host comorbidities such as HIV.
• Resources: MGI (mouse); standard laboratory S. aureus strains (e.g., Newman, MRSA clinical isolates).

Mechanistic Model / Interpretation

The disease is best captured by a two-hit "seed-and-soil" model:

   HIT 1: Transient S. aureus bacteremia        HIT 2: Muscle injury / ischemia
   (from skin, mucosa, minor breach)            (trauma, vigorous exercise)
                 |                                          |
                 +---------------+--------------------------+
                                 v
         Neutrophils carry bacteria into injured, ischemic muscle
         (impaired local clearance = permissive "soil")
                                 |
                                 v   [modulated by host immunocompromise: HIV, DM, neutropenia]
              STAGE 1 (Invasive): diffuse myositis, no abscess  --> antibiotics cure
                                 |
                                 v   [amplified by PVL toxin -> neutrophil lysis, necrosis]
              STAGE 2 (Suppurative): intramuscular ABSCESS      --> drainage + antibiotics
                                 |
             +-------------------+------------------------+
             v                                            v
   Local extension:                            STAGE 3 (Septic):
   osteomyelitis, septic arthritis             bacteremia, metastatic abscesses,
                                               septic emboli, endocarditis, shock

The single most important mechanistic insight—experimentally validated—is that muscle injury is a necessary permissive lesion: intravenous MRSA alone caused no muscle infection in mice, but muscle injury plus bacteremia did (PMID: 28187042). This unifies the epidemiology (young men, antecedent trauma/exercise), the microbiology (S. aureus predilection), and the host risk profile (immunocompromise removes the clearance safeguard). PVL toxin is the principal severity amplifier, converting a localized abscess into complicated, metastatic, and life-threatening disease.

Evidence Base

Limitations and Knowledge Gaps

1. No precise population incidence/prevalence — most data are hospital-based case series or administrative datasets; true community rates are unknown.
2. Culture-negative disease is common (~60% of blood cultures negative), limiting microbiological precision and confounding pathogen-attribution.
3. Selection/referral bias — the literature is dominated by severe, hospitalized cases, likely underrepresenting mild, self-limited disease.
4. Mortality range is wide (1–23%), reflecting heterogeneity in setting, host comorbidity, and diagnostic delay rather than a single true figure.
5. Model limitations — murine models capture bacterial burden and drug response but not the full three-stage natural history or human comorbidities (HIV, chronic abscess).
6. PVL causal weight — much PVL severity evidence is extrapolated from osteomyelitis and other musculoskeletal infections rather than pyomyositis-specific cohorts.
7. No host genetic susceptibility studies — whether host immunogenetic variation modulates risk (beyond overt immunodeficiency) is unexplored.

Proposed Follow-up Experiments / Actions

1. Prospective multicenter registry with standardized staging, imaging, microbiology (including PVL genotyping), and outcomes to establish true incidence, mortality, and stage-specific treatment response.
2. PVL-specific pyomyositis cohort to quantify the independent contribution of PVL to abscess size, multifocality, metastatic spread, and surgical need.
3. Molecular diagnostics (16S/metagenomic sequencing on drained pus) to reduce the culture-negative gap and clarify polymicrobial/atypical etiologies.
4. Refined animal model combining muscle injury + controlled immunosuppression (HIV-surrogate or diabetes models) to recapitulate the full three-stage natural history for therapeutic testing.
5. Host susceptibility study — exome/immunogenetic screening of otherwise-healthy young men with pyomyositis to test for occult immune defects (e.g., neutrophil-function variants).
6. Prevention trials targeting decolonization plus risk-factor optimization in high-risk groups (HIV clinics, dialysis units, PWID programs), given waning decolonization effectiveness and rising resistance.
7. Early-detection pathway validating point-of-care ultrasound + inflammatory markers to catch invasive-stage disease and increase the fraction cured without drainage.

Report compiled from 15 confirmed findings and 58 reviewed papers across 5 investigation iterations. Pyomyositis is characterized here as an acquired, non-genetic infectious disease; sections addressing causal genes, inheritance, and genetic screening are marked Not Applicable and reflect true biology rather than missing data.